| Literature DB >> 29589280 |
Xuemei Wu1, Suli Wang1, Xingyu Lu1, Wenyi Shen1, Chun Qiao1, Yujie Wu1, Ruinan Lu1, Shuai Wang1, Jianfu Zhang1, Ming Hong1, Yu Zhu1, Jianyong Li1, Guangsheng He2.
Abstract
To assess response to cyclosporine A, and/or corticosteroids, and possible factors influencing the response in adult patients with acquired pure red cell aplasia (PRCA). Clinical data from 42 cases were retrospectively analyzed. These patients received cyclosporine A (CsA), and/or corticosteroids (CS), or other immunosuppressive agents on becoming refractory and relapse. Thirty-nine patients were evaluated. Remission induction therapy included CsA (n = 16), CS (n = 13), CsA in combination with CS (n = 6), or other immunosuppressive agents (n = 4). Initial response rates were 75.0, 46.2, 66.7 and 75.0%, respectively (P = 0.456). Cumulative response rates in patients who received CsA, CS, CsA in combination with CS, or other immunosuppressive agents were 69.6% (16/23), 50.0% (7/14), 71.4% (5/7), 42.9% (6/14), respectively (P = 0.376). Cumulative rates of CR were 26.1% (6/23), 28.6% (4/14), 57.1% (4/7), 14.3% (2/14), respectively (P = 0.284). In 27 refractory and relapsed PRCA patients, 11 of 17 patients (64.7%) achieved remission by CsA and/or CS regimen, while three of ten patients (30.0%) responded to other immunosuppressive agents (P = 0.120). CsA and/or CS were effective in treating PRCA. For patients with relapse or refractory PRCA, there were no satisfactory treatments if CsA and/or CS failed or were not administered.Entities:
Keywords: Corticosteroids; Cyclosporine A; Pure red cell aplasia
Mesh:
Substances:
Year: 2018 PMID: 29589280 DOI: 10.1007/s12185-018-2446-y
Source DB: PubMed Journal: Int J Hematol ISSN: 0925-5710 Impact factor: 2.490